POSIFLEX-TECHNOLOGY
15.7.2024 09:03:26 CEST | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce its latest flagship POS terminal series – Mozart BT. The Mozart BT Series introduces beautiful modular monitor systems that integrate high-performance computing power, the latest operating system, and user-friendly ergonomic designs. With a high degree of modularity in construction and sleek elegance in appearance, the series conceals all cables and connectors, perfectly integrating the printer, providing a sense of space economy and aesthetics that enhances Posiflex's brand identity. The small and clean footprint of the Mozart BT Series allows seamless integration into various commercial spaces such as fashion boutiques, hospitality, convenience stores, food and beverage establishments, or multifunctional storefronts. Designed for versatility, it is an ideal solution for businesses requiring an additional display on the counter board for advertising playback, offering an elegant, beautiful, and useful POS terminal solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714496907/en/
Posiflex Mozart BT Series POS Terminals (Photo: Business Wire)
A Harmonious Work of Paper-Thin Elegance
Posiflex's Mozart BT Series, aptly named, strives to unite all its structural, functional, and aesthetic elements into a seamless harmony, reminiscent of a Symphony composition. Following the design principle of "less is more," the thinner display, host, and stand, along with narrower monitor bezels, not only reduce the system's size and weight but also enhance its functionality. Every curve and angle is meticulously crafted to convey a sense of elegance. Integrated and concealed designs ensure the elimination of exposed cables and connectors, presenting a clean and uncluttered aesthetic. The overall outcome is a sleek, harmonious, and elegant masterpiece.
Ripple Brand Identity
The ripple icon on the start button and thermal printer gives a sense of brand identity, symbolizing the continued vitality and the continuous quest for innovation and user benefit. The burgundy red on the sides of the stand suggests understated luxury and the deep, round taste associated with red wine.
Brilliant Modularity
Modular design has consistently been the pinnacle of innovation in Posiflex products, and the Mozart BT Series has elevated modularity to new heights. Each main component, from displays to the host and thermal printer, is independent, facilitating easy installation, removal for repair and maintenance, yet seamlessly integrates in function and structure when assembled into the system. The thermal printer is cleverly incorporated into the stand, becoming an integral part of the POS terminal base. Alternatively, it can function independently, showcasing a design that optimizes both space and functionality ingeniously.
User-Friendly Ergonomic Designs
The Mozart BT Series POS terminal incorporates ergonomic designs to optimize the user experience. Narrow bezels on the displays minimize interference with the user's view, directing attention to the screen. Moreover, the adjustable angles of the displays cater to the user's comfort and dynamic needs. Both main and secondary displays can be vertically oriented, aligning with current market trends. Additionally, all peripherals are positioned at the same level from the user's perspective, promoting heightened comfort.
State-of-the-Art Specifications
The Mozart BT Series POS Terminal stands out with a host of impressive features. It runs on the latest operating systems, including Android 13 with EDLA certified (GMS) or Windows 11 OS, available in both x86 and RISC variants. The terminal is powered by up to the latest 13th-generation Intel processor, ensuring top-notch performance. Users can choose between a 15" or 15.6" LCD display, notably the 15.6" main screen featuring oTP technology (typical 400 nits) for vibrant colors and high brightness. Plus, the terminal offers versatility with accessory and attachment choices, including the 3-in-1 side attachment for RFID/MSR/FPU, iButton, 2D BCR (discrete/side attached), and the detachable printer.
These features combine to provide a powerful and versatile electronic POS system with high-speed processing power and the ability to run the latest applications to meet the changing needs of the retail and hospitality industry.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714496907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom